

1 **Title:** COVID-19 vaccination atlas: an integrative systems vaccinology approach

2 **Authors:** Wasim Aluísio Prates-Syed^{1,2,16}, Dennyson Leandro Mathias da Fonseca³, Shahab
3 Zaki Pour⁴, Lena F Schimke², Aline Lira^{1,2,16}, Nelson Cortes^{1,2,16}, Jaqueline Dinis Queiroz
4 Silva^{1,6,16}, Evelyn Carvalho^{1,6,16}, Igor Salerno Filgueiras², Tania Geraldine Churascari
5 Vences⁵, Lorena C. S. Chaves⁷, Gerhard Wunderlich⁵, Ricardo Durães-Carvalho^{4,8}, Niels O.
6 S. Câmara¹, Haroldo Dutra Dias¹², Hans D. Ochs¹¹, José E. Krieger¹⁰, Helder I Nakaya^{6,13},
7 Otávio Cabral-Marques^{1,3,6,15,16,+}, Gustavo Cabral-Miranda^{1,2,6,16,+,*}.

8 **Emails:** wasim.syed@usp.br, dennyson@usp.br, shahab.178@gmail.com,
9 igor.filgueiras@usp.br, lenaschimke@hotmail.com, cv.tania@usp.br, aline.lira@usp.br,
10 nelson.cortes@usp.br, jaquelinedinis@gmail.com, evelyn.carvalho@unesp.br,
11 lorenacschaves@gmail.com, gwunder@usp.br, rscarval@gmail.com, niels@icb.usp.br,
12 harolddodd@gmail.com, hans.ochs@seattlechildrens.org, sabinoec@usp.br,
13 j.krieger@hc.fm.usp.br, hnakaya@usp.br, otavio.cmarques@usp.br, gcabral.miranda@usp.br

14 **Affiliations:**

- 15 1. Department of Immunology, Institute of Biomedical Sciences (ICB), University of
16 São Paulo (USP), São Paulo, Brazil.
- 17 2. The Interunits Graduate Program in Biotechnology of the University of São Paulo, the
18 Butantan Institute, and the Technological Research Institute of the State of São Paulo,
19 Brazil.
- 20 3. Interunit Postgraduate Program on Bioinformatics, Institute of Mathematics and
21 Statistics (IME), University of Sao Paulo (USP), Sao Paulo, Brazil.
- 22 4. Laboratory of Molecular Evolution and Bioinformatics, Department of Microbiology,
23 Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil;
- 24 5. Department of Parasitology, Institute of Biomedical Sciences (ICB), University of São
25 Paulo (USP), São Paulo, Brazil.
- 26 6. Department of Clinical and Toxicological Analyses, School of Pharmaceutical
27 Sciences, University of São Paulo, São Paulo, Brazil.
- 28 7. Department of Microbiology and Immunology, School of Medicine, Emory
29 University, Atlanta, Georgia, United States.
- 30 8. São Paulo School of Medicine, Department of Microbiology, Immunology and
31 Parasitology, and Department of Morphology and Genetics, Federal University of São
32 Paulo (UNIFESP), São Paulo, SP, Brazil.
- 33 9. Department of Infectious and Parasitic Diseases, Faculty of Medicine, University of
34 São Paulo, São Paulo, Brazil
- 35 10. Heart Institute, Clinical Hospital, Faculty of Medicine, University of São Paulo,
36 Brazil; Laboratory of Genetics and Molecular Cardiology, Clinical Hospital, Faculty
37 of Medicine, University of São Paulo, Brazil.
- 38 11. Department of Pediatrics, University of Washington School of Medicine, and Seattle
39 Children's Research Institute, Seattle, WA, USA.
- 40 12. Department of Neuroscience, Institute of Biomedical Sciences, Federal University of
41 Minas Gerais (UFMG), Belo Horizonte, Brazil
- 42 13. Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
- 43 14. DO'R Institute for research, São Paulo, Brazil
- 44 15. Department of Medicine, Division of Molecular Medicine, University of São Paulo
45 School of Medicine, São Paulo, Brazil.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

46 16. Institute of Tropical Medicine, Faculty of Medicine of the University of São Paulo,
47 Brazil

48 *Correspondence to: gcabral.miranda@usp.br or gcabral.miranda@gmail.com, Gustavo
49 Cabral-Miranda, Institute of Tropical Medicine, Faculty of Medicine of the University of São
50 Paulo, Brazil

51 + Equal contribution as supervisor and senior author.

52 **Abstract:**

53 The COVID-19 vaccinations have played a significant role in controlling the pandemic. To
54 elucidate their impact on the immune system, a COVID-19 vaccination atlas was developed
55 through an integrative systems vaccinology approach. The atlas includes both healthy
56 individuals and those infected with or without prior vaccination, and covers the administration
57 of five vaccines in different regimens: Covilo®, Zifivax®, Vaxzebria® or Covishield®,
58 Spikevax®, and Comirnaty®. Critical markers were identified to discriminate the different
59 types of vaccines and infection, in which infection was associated with GATA3, ZNF3,
60 KMT2A, ASXL1, SP100, and GZMM, and vaccine types were marked by ITGAM, ACTG1,
61 LGALS3, and STAT5B. Additionally, the immunological signatures of heterologous
62 vaccination and infection were described, and it was also shown how a full vaccination
63 regimen markedly limited the shift of immune responses during natural infection, thereby
64 constraining disease progression. Finally, the common transcripts shared across COVID-19
65 vaccines and vaccines against other pathogens were described.

66 Main text

67 1. Introduction

68 Coronavirus Disease 2019 (COVID-19) is a respiratory disease caused by Severe
69 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with its first documented
70 outbreak in Wuhan, China, in 2019¹. The emergence of variants of concern (VOCs) urged
71 adjustments in strategies to effectively control their spread due to the heterogeneity of
72 symptoms, severity, transmission, and decreased efficacy of vaccines against new VOCs,
73 especially the Omicron variant (Chung et al., 2021; Xia et al., 2022).

74 Remarkably, it is estimated that COVID-19 vaccinations prevented more than 14
75 million deaths in only one year after global vaccination enrollment⁴. This was accomplished
76 by breakthrough innovations in vaccinology, in addition to global efforts to fund worldwide
77 clinical trials, including classical and new-generation vaccines⁵. The mRNA vaccines (RNA)
78 Comirnaty® (BNT162b2, BNT) and Spikevax® (mRNA-1273, MO), the viral vectored (VV)
79 vaccines Covishield®/Vaxzevria® (AZD1222, ChAdOx-1, ChAd) and Jcovden® (Janssen),
80 and inactivated vaccines (IN) such as Coronavac® and Covilo® (BBIBP-CORV, BBIBP)
81 were among the first and most used vaccines worldwide until 2023⁶. Particularly, ChAd and
82 BNT were the most used vaccines during the first years of vaccination and 2 and 3-dose
83 heterologous regimens were widely used and assessed^{7,8}. The combination of different
84 vaccines and platforms shows how classical and new-generation vaccines can help control
85 epidemics and potentially trigger complementary systemic immune responses that individual
86 vaccine technologies are intrinsically incapable of⁸⁻¹¹. The complete homologous vaccination
87 regimen showed high efficacy in clinical trials against COVID-19, as high as 95.0%, 94.1%,
88 and 90% for new-generation vaccines, such as BNT, MO, and ChAd, respectively¹¹⁻¹³.
89 Classical technologies, such as inactivated virus (IN), and protein subunit (SU) vaccines, have
90 also shown high efficacy and effectiveness. BBIBP and Zifivax® (ZF2001) had 78.1% and
91 75.7% efficacy against symptomatic infections, respectively^{14,15}. Although these vaccines
92 were initially tested and approved in homologous regimens, heterologous vaccination has
93 been tested in clinical trials and real-world scenarios to address ongoing waves of infection
94 and new VOCs^{8,16}.

95 To understand how different vaccination regimens and vaccine technologies affect the
96 immune system in healthy individuals and infected patients during, and after infection by
97 SARS-CoV-2, it was integrated RNAseq data from five distinct studies that include
98 vaccinations with Covilo®, Vaxzevria® or Covishield®, Spikevax®, Comirnaty®, and
99 Zifivax®. These studies, however, present data from different time points, populations and
100 regimens, and there is a need to obtain a unified perspective of their immunological signatures.
101 This study introduces a systems vaccinology atlas that delineates shared and individual
102 profiles across conditions in both healthy and infected individuals. The findings indicate that
103 completing a vaccination regimen can effectively limit disease progression. Additionally, it
104 demonstrates that heterologous vaccination strategies can diversify immunological signatures,
105 potentially enhancing protection against the disease. Furthermore, the study explores immune
106 responses induced by vaccines targeting other pathogens and reveals a substantial overlap in
107 genes related to the innate immune system with COVID-19 vaccines.

108

109 2. Results

110 Immune-related gene expression varies by vaccine type, regimen, and infection status.

111 A total of 562 samples were analyzed, sourced from peripheral blood mononuclear
112 cells (PBMCs) of 245 participants involved in five distinct studies (**Table 1, Fig. 1A**). These
113 participants were either vaccinated (V) with one or more of the four different types of vaccines
114 (IN, SU, RNA, and VV), which comprised both homologous (HO) and heterologous (HE)
115 vaccination regimens and were administered in one (V1), two (V2), or three doses (V3), or
116 were infected patients (I) with or without prior vaccination (**Fig. 1B-C, Fig. S1-2**). Many
117 issues were identified with the GSE206023 count matrix, in which most of the genes were
118 annotated in GenBank IDs with multiple identifier versions for the same genes. Moreover,
119 only 10% of these identifiers could be annotated, comprising less than 2% of the immune
120 genes, in contrast to more than 90% present in the other datasets. Given the importance of this
121 dataset regarding the diversity of vaccine technologies, a decision was made to reprocess the
122 read files in FASTQ and align it with the reference transcriptome using pseudoalignment in
123 the Kallisto package¹⁷. While other datasets employed HISAT2, pseudoalignment was chosen
124 due to its superior speed, robustness, and lower computational resource requirements
125 compared to HISAT2.¹⁸

126 The temporal dynamics of differentially expressed genes (DEGs) was influenced by
127 vaccine type, number of doses, and administration regimen. This happened across
128 convalescent and non-convalescent individuals, as well as infected patients with previous
129 vaccination (**Fig. 2A, Fig. S3**). Notably, the BNT vaccine exhibited a significant increase in
130 total DEGs across the three doses, with three DEGs six days after the first dose (BNT V1),
131 followed by 613 and 96 DEGs 1 day after the second (BNT V2) and third doses (BNT V3),
132 respectively, with a more substantial increase with two doses of BNT followed by a single
133 dose of MO (BNT-MO V3) (**Fig. 2A**). In contrast, it was observed that the ChAd vaccine
134 exhibited a divergent pattern compared to BNT in non-convalescent individuals, with
135 decreased up- and downregulated DEGs over the first week after two homologous doses
136 (ChAd V2), and a higher number of DEGs in the heterologous vaccinations (ChAd-BNT V2
137 and ChAd-BNT V3) (**Fig. 2A, Fig. S3**). A similar trend was observed in homologous and
138 heterologous vaccinations with the BBIBP vaccine after a third dose (**Fig. 2A, Fig. S3**). It was
139 evident that homologous vaccination with an inactivated virus vaccine does not generate
140 significant DEGs in a third dose (BBIBP V3) and thus requires heterologous vaccination with
141 a different technology, such as a SU vaccine (ZF2001 V3) (**Fig. 2A, Fig. S3**).

142 Furthermore, infections in vaccinated and unvaccinated patients notably affected the
143 number of downregulated DEGs (**Fig. 2A, Fig. S3**). Among unvaccinated infected
144 individuals, DEGs were higher in severe disease cases than in moderate cases over 51 days.
145 Conversely, in infected patients with prior complete vaccination, primarily mild and moderate
146 disease, this number was at least 10 times lower. However, infected hospitalized patients with
147 moderate and severe disease who were vaccinated with a single dose of BNT 10-11 days
148 before hospitalization, the number of DEGs was similar to that of infected patients on days 10
149 and 26. This pattern could also be influenced by the age range (71-90 years) of these patients,
150 which is a major risk factor for COVID-19¹⁹. Of the four infected patients, three recovered,
151 and one died (**Fig. S3**). The surviving patients continued dexamethasone treatment and
152 received a second dose of the vaccine 40 days post-infection²⁰. Samples were collected 15-20
153 days post-vaccination, exhibiting more DEGs than at a later time post-vaccination in non-
154 convalescent individuals with BNT or ChAd (**Fig. 2A**). The gene expression patterns in
155 unvaccinated and single-dose vaccinated patients during the second infection were similar,

156 but vaccinated individuals exhibited a notable, threefold reduction in DEGs compared to with
157 unvaccinated counterparts. Only in the total DEGs analysis, without discriminating by
158 ontology (immune and non-immune), was an apparent relationship between vaccine type,
159 disease severity, and time.

160 Upon filtering immune-related DEGs, it became clear that the fraction of immune-
161 related genes decreased over time in vaccinees and infected patients (**Fig. 2A, Fig. S3**).
162 Specifically, this investigation focused solely the immune-related genes excluding genes from
163 the BCR and TCR repertoire [immunoglobulin chains (IG@) and T-cell receptors (TR@)].
164 Particularly in infected patients, the first days showed a greater fraction of immune genes,
165 which decreased over time, whereas the number of other non-immune-related genes increased
166 (**Fig. 2A, Fig. S3A**). In addition, infected patients with prior complete immunization showed
167 fewer DEGs and a smaller fraction of immune genes. Nevertheless, vaccination results in the
168 activation substantially more immune genes, which follow proportionally to other genes,
169 either increasing or decreasing, depending on the vaccine type. This contrast indicates that the
170 immune response induced by vaccines is quantitatively more balanced in terms of the
171 expression of immune genes than infection. To identify patterns among these conditions,
172 immune-related and non-immune DEGs were compared distinctively ($q\text{-value} < 0.10$) (**Fig.**
173 **2B, Fig. S4A**). It was observed that the majority of shared genes among the different vaccine
174 types were non-immune genes, such as ANKRD22, GBP1P1, GPRB4, and HES4 (**Fig. S4A-**
175 **B**). Moreover, the most shared genes, such as LRRN3, ADAMTS2, and FAM209B, were
176 more present among infected patients (**Fig. 5B**). This shows the role of other processes in
177 vaccination and, to a greater extent, infection.

178 To understand these non-immune processes during vaccination, the analysis focused
179 on the non-immune genes. It was found that a majority of these genes were related to
180 ubiquitous cellular and metabolic processes, and the regulation of biological processes (**Fig.**
181 **2A-B, Fig. S4**). However, the subsequent analysis specifically targeted immune genes. The
182 shared immune DEGs exhibited one central cluster associated with the groups infected for the
183 first time (vaccinated and unvaccinated) and another cluster comprising the first day of
184 vaccination with homologous or heterologous second and third doses of ChAd, BNT, and MO
185 (**Fig. 2B**). Notably, the number of shared genes among infected groups was 2- to 10-fold
186 higher than non-convalescent-vaccinated groups. In addition, it was observed a decrease in
187 shared DEGs between infected patients with prior vaccination (BNT-I) and infected patients
188 with prior infection and prior vaccination (I-BNT-I), in a similar proportion to non-
189 convalescent vaccinated groups, which was not evident in the non-immune DEGs context
190 (**Fig. 3B, Fig. S4A**). This finding was also associated with vaccine type, viral vector vaccines
191 (ChAd and ChAd-BNT), and subunit vaccines (ZF2001), which were more evident with non-
192 immune DEGs (**Fig. S4A**).

193 In contrast, there was a noticeable decrease in the number of genes on subsequent days,
194 particularly on day 7, suggesting the initiation of homeostatic processes over time. This
195 reduction in DEGs becomes more pronounced on subsequent days. However, this decrease
196 contrasts with the trend observed with increasing doses, particularly notable in homologous
197 RNA vaccines and heterologous ChAd with subsequent vaccination with BNT. This indicates
198 a broader activation of diverse genes with a higher number of doses. Particularly, vaccination
199 with BNT following one or two doses of ChAd led to a significantly greater number of total
200 DEGs compared to the two-dose homologous regimen of either vaccine (**Fig. 2A-B, Fig. S4**).
201 Comparing to the two doses of ChAd on day 3, there was a three-fold increase in upregulated
202 DEGs, which reduced by half on day 7. Conversely, downregulated DEGs were 13-fold higher

203 in the ChAd-BNT regimen but increased two-fold on day 7. Remarkably, even though the
204 assessment was conducted only one day post-vaccination, upregulated DEGs exhibited in the
205 ChAd-ChAd-BNT regimen were approximately two-fold higher than those with two doses of
206 ChAd and 1.2-fold higher than those with BNT-MO.

207 In contrast, the number of up- and downregulated genes was nearly equivalent in
208 infected individuals, regardless of prior vaccination status (**Fig. 2A, Fig. S4A**). Additionally,
209 genes from unvaccinated infected individuals were largely constrained within their group and
210 had a limited overlap with vaccinated individuals.

211 To describe the immune transcriptome of individual vaccination regimens, we
212 compared all the genes present in the datasets with the immune system related genes (**Fig.**
213 **4D**). Following this comparison, the enrichment of gene sets associated with immune
214 responses was analyzed. (**Fig. 4C**).

215 **Limited Immunological Profile Observed with Three Homologous doses of BBIBP**

216 The BBIBP exhibited enrichment of processes associated with the innate immune system,
217 including the antiviral response mediated by interferons, neutrophils, eosinophils, and
218 monocytes, which were consistently found to be negatively regulated (**Fig. 4C**). Further
219 analysis of gene expression within these processes and cells revealed specific genes of interest
220 (**Fig. S4-7**). On day 14, we identified genes associated with inflammation (NLRP9,
221 upregulated), immune regulation (IDO2), macrophage-mediated antiviral response (CCL3,
222 downregulated), neutrophil activation (CXCL8), and lymphocyte-macrophage signaling
223 (WNT4, upregulated)²¹. On day 28, a transcription factor (NFKBIA, downregulated) present
224 in ARPP and B cells, which regulate immune system processes, and CCL2 (downregulated),
225 a monocyte chemokine, were observed.

226 **ZF2001 as Heterologous Booster Elicits Distinct Immune Response Profile**

227 A heterologous regimen with the ZF2001 vaccine in individuals who had previously received
228 two doses of the BBIBP vaccine resulted in a distinct gene expression profile compared to the
229 homologous vaccine. Although most DEGs were upregulated, a small fraction of genes related
230 to the immune system were downregulated (**Fig. 2A**). On the seventh day post-vaccination,
231 there was a suppression of genes associated with inflammatory processes (IL1RN, FOSL2,
232 and CD58), antiviral response and interferons (CXCL2, CXCL3, CCL3, CCL4, CCL20,
233 BCL3, ADM, LGALS3, FAU), as well as genes related to antigen recognition and
234 presentation (TNFAIP3, FOSL1, RAB3B, and ICAM). This suppression also extended to
235 genes expressed in eosinophils (VAMP2), NK cells (RNF19B), dendritic cells (NFKBIA,
236 FOSL1), T cells (IL2), B cells, and immunoglobulin-mediated responses (BCL3, BCL6) (**Fig.**
237 **2C, Fig. S6-9**).

238 On the other hand, a predominance of upregulated genes was observed on the seventh day,
239 particularly associated with other chemokines (CX3CL1, CXCL8, CXCL14, CCL8,
240 CX3CL1), mast cells (CPLX2, CLNK, LGALS3), ARPP (ITGB8, TRIL), APCs (ADGRF5,
241 FLT1, IL33, WNT4), adaptive response processes and cells (CACNB4, EOMES, SPNS2,
242 BCAR1), as well as the complement system (**Fig. S6-9**). Specifically, within the complement
243 system, genes from the classical pathway (C4B and C4BPB) and lectins (MASP1 and
244 MASP2) were overexpressed (**Fig. S6-9**). In the adaptive immune system, there were genes
245 related to T cell activation (IL13, EPHB1, TNFAIP8L2, TARM1), specifically Th2 response

246 (IL33), Th17 (CCR2), TCD8 (EMP2), B cell and Ig-mediated response (WNT3A) (**Fig. S6-**
247 **9**).

248 **Viral Vecteded Vaccine ChAd Induces Early Gene Expression of Complement and** 249 **Adaptive Immune Systems**

250 Genes related to T cells and the cellular response to the viral vector were expressed as early
251 as the third-day post-vaccination with the first dose. Notably, genes such as CCNB2 and
252 CAV1, which play roles in the cell cycle and T cell activation, respectively, exhibited
253 sustained expression levels up to the seventh day. Additionally, the innate immune system
254 processes are enriched, including interferon-mediated antiviral responses, acute phase
255 response proteins (ARPP), and NK cell, related proteins along with upregulated genes from
256 the complement system associated with the alternative pathway (CFB and CFD) (**Fig. S7-9**).

257 It is also essential to highlight the distinct expression of genes related to humoral responses
258 on the third and seventh days (**Fig. S8**). These expression patterns were also observed in B-
259 cell genes, with overexpression between days 3, 6, and 7, returning to the initial profile by the
260 sixth day. Conversely, except for genes associated to cellular response, B cells processes, and
261 the humoral immune response were enriched on the first day after the second dose. However,
262 gene-level analysis still revealed diverse and high gene expression at this stage, especially for
263 the cytokine CCL2 and immunoregulatory enzyme IDO1. When comparing genes related to
264 the humoral response between doses, it was noted that these genes were less expressed and
265 less diverse at the second dose. On the third day, only two DEGs associated with the humoral
266 response were identified (SYK and KIT). Particularly, on day 7, CD27, a gene involved in
267 immunoglobulin synthesis,²² was increased after the first dose and suppressed after the second
268 dose.

269 **Distinct Gene Expression Patterns Elicited by mRNA Vaccines BNT and MO**

270 The mRNA vaccines BNT and MO demonstrate distinct gene expression patterns. Six days
271 after the first dose of BNT, only 3 DEGs were identified, with IFI27 being the only immune-
272 related gene (**Fig. 2A, Fig. S4-7**). Subsequent second and third BNT doses revealed elevated
273 activation of antiviral and interferon responses, ARPP, and the function of neutrophils,
274 eosinophils, monocytes and dendritic cells (**Fig. 4C**). These sets were similarly enriched
275 following the third homologous vaccination, except for dendritic cells. A third heterologous
276 vaccination with MO induced dendritic cell function, inflammation, and the activation of the
277 cellular adaptive immune system. Notably, IFI27 expression was exclusive to all BNT doses
278 except for the third dose of MO (**Fig. S4-7**). Neutrophils shared genes in various vaccination
279 regimens, including CCL8, CXCL9, and CCL2 (**Fig. S4-7**)²³. In addition, eosinophils
280 exhibited pronounced CCL3L1 expression following MO vaccination, which plays a pivotal
281 role in virus clearance from the lungs²⁴.

282 **Immune Signatures in Infected and Convalescent Patients Before and After Vaccination** 283 **with BNT**

284 To understand the impact of vaccination before and after infection, we analyzed infected and
285 convalescent patients. We found that innate immune cells and processes were highly activated
286 and persisted for several days, especially interferons 1 and 2, neutrophils, APCs, and
287 bacterium-directed PRRs (TLR4 and NOD) (**Fig. 4C, Fig. S4-7**). Additionally, B-cell
288 processes, including chemotaxis and homeostasis, are activated (**Fig. 4C, Fig. S4-7**). There
289 was also a Th2 response in BNT-I (D26, mild), although T cell processes were predominantly

290 downregulated under other infection conditions. In a gene-level analysis, many genes related
291 to the adaptive immune system were upregulated and downregulated. Likewise, it was evident
292 that infection induced different subsets of genes compared to vaccination in every immune
293 process and cell type (**Fig. S4-7**). Considering the innate immune system and classical
294 pathway complement system genes (such as CR1 and C1R), high and persistent gene
295 expression, especially those associated with inflammation (e.g., IL10, HMGB2, ELANE, and
296 NLRP6), activation of neutrophils (e.g., CD177, ANXA3, and IL18RAP) and mast cells (e.g.,
297 S100A12 and SLC15A4), may be associated with the initiation of cytokine storms, allergic
298 reactions, and thrombosis^{25,26}. Although most genes participating in adaptive immune system
299 processes were highly downregulated, there were also many highly expressed genes in the
300 humoral response, including genes related to Ig-mediated responses, ARPP, and other B-cell
301 processes, as well as in cellular response and T- cell processes. This pattern varied among
302 convalescent and infected patients who had received prior vaccination, regardless of whether
303 they had a completed or incomplete vaccine regimen (**Fig. S4**).

304 **Stratification of COVID-19 vaccination and infection using multivariate analyses**

305 To describe the similarities and differences among all conditions, it was conducted a
306 Principal components analysis (PCA) with all immune DEGs (**Fig. 3A-D**). Principal
307 component 1 (PC1) accounted for 66.8% of the variance, whereas PC2 accounted for 15.7%,
308 totaling 81.9%. PC1 was predominantly defined by genes associated with interleukin (IL)
309 signaling pathways (IL18RAP, SOS2, MAP2K6), apoptosis (HMGB2), inflammation-related
310 processes (RC3H1, ALOX5, PPARG, and FCER1A), as well as processes linked to
311 lymphocytes (ETS1), particularly to T cells (VNN1, CD6, TESPA1, RPL22, PCLG1, TCF7,
312 TRAT1, and CD3G) (**Fig. 3C**). On the other hand, PC2 was defined by genes related to
313 antiviral and interferon responses (IFI35, IFITM3, STAT1-2, IDO1, ADAR, BST2, GBP1,
314 and PML), as well as APCs (BATF2, LILRB1) and antigen receptors, processing and
315 presentation (ARPP) (TAP2, PDIA3, TRIM26, and CTSS) (**Fig. 3D**).

316 The results revealed the presence of three primary clusters (**Fig. 3A**). The first
317 significant cluster indicated patients with ongoing infection, characterized by genes associated
318 with IL-signaling pathways, apoptosis, and inflammation-related processes in cluster 1 (**C1**;
319 **Fig. 3A,C**). While this cluster included specific individuals with previous vaccination, we did
320 not anticipate a substantial influence of vaccination, particularly considering that it was
321 administered 10 days before the onset of COVID-19 symptoms. Nevertheless, it is evident
322 that patients who received a complete vaccination regimen and were subsequently infected
323 (BNT-I), as well as a patient who received a second dose of BNT 10 days after recovery
324 (BNT-I-BNT, D51), showed overlap with Cluster 2 (C2). The C2 cluster comprises
325 homologous vaccinations for both convalescent patients and non-convalescent individuals.
326 Additionally, healthy-vaccinated individuals were part of this cluster, but it also included
327 patients with two infections (without severe outcomes) and one patient initially experiencing
328 severe disease 51 days after the onset of symptoms, who were hospitalized and treated with
329 steroids. Given that this cluster occupies the central position in the plot and represents
330 comparatively healthy conditions, the proximity of eigenvalues from the first cluster to the
331 second cluster suggests an ongoing, time-dependent homeostatic process. In contrast, the third
332 cluster (C3) consisted of homologous and heterologous vaccinations involving genetic-based
333 vaccines such as BNT, ChAd, and MO, specifically within the initial three days post-
334 vaccination. This cluster is characterized by genes in PC2 and shares a minimum number of
335 certain genes with infected patients in C1. Nevertheless, the expression of the top 20
336 contributing genes in PC2 was significantly higher in C3 than in C1 conditions (**Fig. 3B,D**).

337 These differences were marked by genes such as IDO1, IL31RA, and LILRB1, which were
338 not expressed during infection and are associated with antimicrobial response, chemotaxis,
339 and MHC1 presentation, respectively.

340 **Machine learning classification of COVID-19 vaccine types and infection based on** 341 **immune genes**

342 Using the PCA results, genes in PC1 and PC2 ($\cos^2 > 0.5$) were filtered and a random
343 forest model was trained for classification based on the variable “type”, including infection
344 and the different vaccine types (**Fig. 4A**). This model demonstrated remarkable performance,
345 with an accuracy of 91.2%, an area under the receiver-operator curve (ROC) of 0.990, and an
346 out-of-bag (OOB) error of 0.086. The main gene predictors were associated with
347 transcriptional regulation (GATA3, ZNF3, KMT2A, and ASXL1), antiviral response
348 (SP100), granzyme (GZMM), ARPP (ITGAM, ACTG1, LGALS3), and T cell response
349 (STAT5B) (**Fig. 4B**). The high expression of the transcriptional regulation associated genes
350 GATA3, ZNF3, KMT2A, and ASXL1, an antiviral response gene (SP100), and the granzyme
351 GZMM, were key markers for infection, along with the suppression of genes that play roles
352 in ARPP (ITGAM, ACTG1, LGALS3), and T-cell response (STAT5B) SP100 was also
353 notably expressed in vaccination, in the first 3 days after the second and third doses of both
354 homologous and heterologous regimens. LGALS3 was also markedly expressed in the first 3
355 days of vaccination with ChAd. This observation aligns with the fact that viral vectored
356 vaccines, like ChAd, act through certain infection associated mechanisms to deliver genetic
357 material into the nucleus²⁷.

358 **Comparative Analysis of Vaccines Against Other Pathogens**

359 Understanding how COVID-19 vaccines relate to classical and consolidated vaccines
360 used in routine immunization is essential. Therefore, all immune-related DEGs associated
361 with various vaccines, including COVID-19, were compared using MSigDB Vax collection
362 ²⁸. The dataset was manually annotated and selected all up- and downregulated genes from
363 vaccination-only sets (**see Methods, Fig. 1A**). This approach originated from several gene
364 sets, including those correlated with antibody titers, T-cell responses, and training sets. To
365 understand the extent of gene overlap, was performed a gene-level analysis of these shared
366 genes from PBMC-derived samples, to match the COVID-19 conditions, while filtering DEGs
367 with $-1 < L2FC > 1$ (**Fig. 5A-C, Fig. S8 and 9**).

368 The analysis uncovered a notable overlap of genes, both up- and downregulated,
369 between vaccines targeting viruses and bacteria based on inactivated (IN) and live-attenuated
370 (LA) pathogens and COVID-19 vaccines (**Fig. 5A-C**). This overlap was most prominent in
371 the initial two weeks and following the second and third doses. Specifically, downregulated
372 DEGs were predominantly associated with infection, particularly with LA vaccines (**Fig. 5A**).
373 Conversely, upregulated DEGs were common among vaccinated individuals, comprising both
374 non-convalescent and convalescent individuals. This overlap extended to include infected
375 patients who had undergone prior one-dose vaccination.

376 The observations revealed two main clusters of genes, predominantly representing the
377 innate and adaptive immune systems (**Fig. S6**). While the second cluster encompasses genes
378 present in the adaptive immune system, these genes also exhibit a lower degree of overlap
379 with the innate immune system. Notably, the second cluster appeared more heterogeneous and
380 demonstrated significantly fewer shared genes across vaccines than the first cluster. In this

381 first cluster, we observed that COVID-19 vaccines and others shared most innate genes that
382 also play a role in the adaptive immune system (**Fig. 5D**). Some of the most common genes
383 between vaccines included chemokines and receptors (CCL2, CCL3, CCL8, CCL20, CCR1,
384 and CXCL8), interferons and antiviral responses (IRF1, IFIT1, STAT1, and STAT2), ARPP
385 (TAP1, TAP2, HLA-DMB, and HLA-DMA), and some adaptive immune system genes
386 (RIGI, FAS, CD83, BCL6, and FCER1G) (**Fig. 5B**). On the other hand, some of the genes
387 present mainly in COVID-19 vaccine conditions are chemokines, such as CCL2, which play
388 a diverse role in the innate, adaptive, and complement systems (**Fig. 5C**). CCL2 is also shared
389 with the monovalent influenza vaccine adjuvanted with AS03 and the LA vaccine Fluzone®
390 ²⁹. Although most non-COVID-19 vaccines sharing genes with COVID-19 vaccines are
391 targeted against the influenza virus, Stamaril®, a yellow fever LA vaccine, shares many innate
392 immune system genes with COVID-19 vaccines ³⁰. Indeed, an overrepresentation analysis
393 (ORA, FDR < 0.25) of immune genes showed that general leukocyte processes and antiviral
394 and interferon processes were enriched in most vaccines and vaccine types (**Fig. 5E**). VV
395 vaccines against COVID-19 and tuberculosis (MVA85A) were significantly (qvalue < 0.10)
396 enriched with genes related to eosinophils, monocytes, and neutrophils (**Fig. 5E**).

397 **Discussion**

398 This COVID-19 vaccination atlas comprehensively analyzes the dynamic and diverse
399 immune responses generated by different vaccination strategies against COVID-19. These
400 strategies include homologous and heterologous vaccination regimens, diverse vaccine types,
401 and consideration of prior vaccination status at the time of infection, alongside the time
402 elapsed since infection (**Fig. 1A**).

403 The analysis reveals that immune-related genes constitute a smaller proportion of the
404 total DEGs than other biological processes, including cellular, metabolic, and regulation of
405 biological processes (**Fig. 2A, Fig. S4**). A limitation of this analysis by gene ontology of
406 biological process is that some genes that are not annotated as immune play ubiquitous roles
407 in cellular and metabolic processes present in immune cells. This can also be attributed to the
408 inoculation of immunogens through syringe injection, which leads to local and limited tissue
409 damage at the injection site. Indeed, intramuscular injections are prone to human errors, and
410 questions remain regarding which injection site and procedure are optimal and safest ³¹. This
411 vaccine administration issue and the molecular characteristics of different vaccine platforms
412 might explain reactogenic behavior in some individuals. In the context of infection, this
413 pattern illustrates the regulation of numerous genes influenced by viral infection cycle
414 processes and the host response ^{32,33}. This variability is primarily attributed to diverse response
415 mechanisms among individuals, impacting disease progression or immunity³⁴. However, this
416 aspect will not be discussed in more details since it diverges from the primary objective of our
417 study, which focuses on describing the transcriptome of the immune system. Nonetheless, it
418 is noteworthy as it raises questions regarding non-immunological factors and their role in
419 vaccination and disease development.

420 Moreover, it was found that these DEGs are highly shared between the studied
421 conditions, encompassing both infection and vaccination conditions. In addition, a higher
422 representation of immune-related genes was observed in the vaccination group compared to
423 infection (**Fig. 2A**). Specifically, genes associated with inflammation, the complement
424 system, neutrophil function, antiviral responses, and interferon pathways exhibit prolonged
425 activation during infection, while adaptive immune-related genes are significantly
426 downregulated (**Fig. S4-7**). In contrast, vaccination triggers the activation of chemokines and
427 adaptive immune-related genes.

428 The surge in up- and downregulated DEGs in the early days after the second and third
429 doses of BNT or MO indicates the ability to activate the innate immune response. Considering
430 the rapid mRNA expression, post-inoculation might also trigger antigen-presenting cells to
431 initiate an adaptive immune response³⁵. Notably, despite having the same mRNA platform as
432 BNT and encoding the same spike amino acid sequence, the MO vaccine differs in nucleotide
433 sequence due to codon optimization and the absence of pseudouridine modification^{36,37}.
434 However, whether this substantial increase is attributable to an immune response to the third
435 dose, the technology, or other factors, such as LNP composition, remains unclear.

436 The heterologous vaccination regimen was also explored with different types of
437 vaccines, namely ChAd and BNT, and BBIBP and ZF2001. It was found that it can contribute
438 to the diversification of immune responses, address some of the technological limitations of
439 the vaccine platforms, and consequently enhance protection against COVID-19.

440 The ChAd vaccine contains a chimpanzee adenovirus viral vector that shares epitopes
441 with prevalent human adenoviruses, which can trigger an adaptive immune response against
442 the vector³⁸. It is therefore possible that the administration of multiple doses of the vaccine
443 may generate antibodies targeting the vector, potentially limiting the delivery of genetic
444 material, unlike mRNA vaccines³⁹. Hence, heterologous vaccination is a clinical and
445 immunologically important option, allowing individuals who receive the complete
446 homologous ChAd regimen to obtain better protection through vaccination with vaccines that
447 use different technologies, particularly those based on mRNA^{16,40}. Nevertheless, the
448 discussion regarding the continued efficacy of the ChAd viral vector in these individuals
449 compared to other antigen vaccine formulations is crucial.

450 Heterologous mRNA vaccination regimens, especially those following the ChAd
451 vaccine, demonstrate similarity to the second and third mRNA homologous and heterologous
452 vaccinations. This can be advantageous for a vaccination regimen that is initiated by a VV
453 vaccine and boosted by mRNA vaccines, potentially mitigating the impact of antibodies
454 directed against the viral vector. However, the use of BNT as a third dose after two ChAd
455 doses is mainly associated with antiviral and interferon responses as well as neutrophils.
456 Additionally, as the samples were limited to the first day after vaccination in this condition,
457 we could not assess the impact of these responses on the adaptive immune system.

458 The Covilo®/BBIBP vaccine is an inactivated virus vaccine formulated with alum
459 adjuvant and evaluated in clinical trials with a homologous two-dose regimen (Wang et al.,
460 2020; Al Kaabi et al., 2021; Zhang et al., 2022). The regimen of three homologous doses of
461 BBIBP, specifically when given on days 7, 14, and 28, seems to present a limited
462 immunological profile owing to the nature of the immune response to inactivated viruses⁴³. In
463 a study assessing the effectiveness of two doses of an inactivated influenza vaccine,
464 employing a similar strategy to the development of the BBIBP vaccine, significant changes
465 in gene expression were not observed one week after the second dose. Additionally, no
466 considerable antibody titers were recorded, corroborating the BBIBP vaccine data⁴⁴.
467 However, in another BBIBP vaccine study, this limited immunological profile was not
468 observed, in which a second boost induced more robust humoral and cellular immune
469 responses detected after two weeks⁴⁵. Despite the limited data regarding the efficacy of a third
470 dose, it is evident that employing a homologous vaccination strategy with three doses of the
471 inactivated BBIBP vaccine may offer limited immunological benefits. Nevertheless, the third
472 dose demonstrated significant efficacy against the disease¹⁵. It is important to emphasize the
473 need to evaluate the immune transcriptome after the first two doses in samples from infected
474 patients who have received two or three vaccinations⁴². Furthermore, investigating the early

475 stages of vaccination, regardless of the number of doses administered, could provide valuable
476 insights into identifying the genes linked to the innate immune response.

477 The Zifivax®/ZF2001 vaccine was not initially evaluated at the onset of the pandemic
478 when the population had not yet been vaccinated. Instead, it was assessed as a booster dose in
479 individuals who had previously received two doses of the BBIBP vaccine¹⁵. As expected, in
480 a heterologous regimen, vaccination resulted in a distinct gene expression profile when
481 compared to the homologous vaccine¹¹. These findings suggest that immunological memory
482 plays a pivotal role in the first-week post-vaccination, and antibodies generated by the
483 inactivated vaccine recognize, opsonize, and trigger a response to the ZF2001 vaccine protein
484 through the classical pathway of the complement system. Additionally, the original study
485 revealed a significantly higher antibody titer than the homologous regimen, supporting the
486 importance of heterologous vaccination¹⁵.

487 Importantly, the findings demonstrate the significant contribution of complete vaccination
488 regimens compared to natural infection and incomplete vaccination. Considering that infected
489 patients with incomplete vaccination were hospitalized 10-11 days after vaccination with a
490 single dose of BNT, infection must have occurred some days before hospitalization, and we
491 anticipated that vaccination would not have protected these patients. In the PCA, individuals
492 with prior-vaccination overlapped between the infected cluster and the vaccination cluster C2,
493 which encompassed homologous vaccinations for both convalescent and non-convalescent
494 individuals, along with healthy-vaccinated individuals (**Fig. 3A**). This overlapping was
495 notable among individuals who were infected after a complete vaccination regimen with BNT.
496 Conversely, an incomplete vaccination regimen was associated with infection, suggesting a
497 limited protection of vaccination administered right before infection. We found that in
498 infected patients with no prior vaccination or with incomplete vaccination the genes related
499 to innate immune cells and processes were highly activated and persisted for several days,
500 especially IFN1 and IFN2, neutrophils, and APCs. Interestingly, bacterium-directed PRRs
501 (TLR4 and NOD) were also highly expressed in these conditions, suggesting that these
502 patients were also coinfecting by bacteria, which is a risk factor for hospitalization⁴⁶.

503 To provide a model of key genes that describe infection and the different types of
504 COVID-19 vaccines, we trained a classification random forest model with 244 genes selected
505 from the PCA. Our model identified the 10 genes that are most important for classification,
506 with high accuracy (91.2%) and sensitivity (ROC AUC of 99.0%), and low OOB ratio (8.6%).
507 The genes that classified infection were associated with transcriptional regulation (GATA3,
508 ZNF3, KMT2A, and ASXL1), antiviral response (SP100), and granzymes (GZMM); vaccine
509 types were marked by ARPP (ITGAM, ACTG1, LGALS3) and T-cell response (STAT5B)
510 (**Fig. 4B**).

511 In addition, we compare COVID-19 vaccines with other vaccines targeting different
512 pathogens, as outlined in the Vax MSigDB dataset (**Fig. 5C**). This comparison is crucial for
513 understanding how new-generation vaccines, such as mRNA-based and viral-vectored
514 vaccines, relate to classical and consolidated vaccine technologies. Given the pivotal role of
515 the innate immune response in the early stages of both vaccination and infection, the
516 overlapping genes identified likely contribute to the innate immune system⁴⁷. In particular,
517 bias in FCER1G towards non-COVID-19 vaccines shows a predominance of Th2 response,
518 presumably due to the widespread use of alum adjuvants, a known Th2 response activator that
519 is used in the formulation of BBIBP and ZF2001⁴⁸. This comparison was notable with
520 influenza IN vaccines and LA vaccines against yellow fever and smallpox, which share
521 common DEGs with COVID-19 vaccines in the initial weeks, especially those related to the

522 innate immune system. Additionally, LA vaccines serve as a valuable reference for a robust
523 immune response, mimicking the wild-type virus infection. The observed overlap of LA
524 vaccines with COVID-19 vaccination conditions adds an intriguing dimension to our findings.
525 The diversity in the immunome in vaccines sharing the same technology may be attributed to
526 the specific and varied nature of the adaptive immune system and other technical limitations
527 of the MSigDB Vax dataset. It primarily relies on transcriptomic data from microarrays, which
528 predates the widespread adoption of high-throughput RNA sequencing. In addition, this
529 dataset lacked gene expression fold-change values, highlighting a constraint in our analysis.

530 Although this study provides valuable insights, there are notable limitations regarding
531 the datasets and transcriptomic analyses utilized. Specifically, the use of only bulk RNA-seq
532 data restricts our understanding of the dynamic and heterogeneous behavior of individual
533 immune cells. Furthermore, collecting vaccination and infection samples at different time
534 points presents a limitation in describing the chronological dynamics of the immune response.
535 Specifically, this difference restricts the characterization of the adaptive immune response in
536 vaccination, predominantly assessed within a one-week period. There are additional
537 challenges in analyzing third-dose vaccinations with BNT, MO, and ChAd, which were
538 assessed on the first-day post vaccination, primarily constraining the analysis to the innate and
539 complement immune systems. These restrictions remain significant despite their
540 interconnectedness with the adaptive immune responses elicited by previous doses. In
541 addition, the analysis of BBIBP and ZF2001 vaccines is restricted by the limited time points
542 on the days during the first week, crucial for the innate immune response, and also did not
543 allow us to compare with the preceding doses. Moreover, the observed gene expression pattern
544 was in agreement with the immunological finding of a study, but was contradictory to
545 another (Aydillo et al., 2022; Ying Chen et al., 2023). Exploring how different vaccine
546 technologies contribute to protecting infected vaccinated individuals, as observed in BNT-
547 vaccinated individuals, would provide further insight.

548 To improve analysis and interpretation by incorporating supplementary data sources,
549 such as antibody titers, neutralizing antibodies, T cell counts, and clinical trial data, would
550 greatly enhance our understanding. Although sex, age, and VOCs data were present, we did
551 not adjust the contribution of these variables to the immunological signatures described.
552 Adopting a multidimensional approach that integrates various datasets and immunological
553 methodologies would offer a more comprehensive understanding of the immunological
554 landscape after vaccination.

555 3. Methods

556 Data curation and processing

557 The selected datasets were first curated using available metadata from Gene Expression
558 Omnibus (GEO) and supplemented with information obtained from pertinent publications
559 (Fig. S1-3, Table 1). We included studies related to SARS-CoV-2 immunization that provided
560 detailed and precise methodology, involved convalescent and non-convalescent patients with
561 or without prior vaccination, and used bulk or single-cell RNA-seq PBMC-derived samples.
562 We excluded studies that lacked methodological descriptions or references, especially
563 concerning sample collection timing between doses, involved TCR and BCR repertoire
564 sequencing, included patients with distinct medical conditions such as autoimmune diseases
565 and cancer, or lacked standardized count matrices. The count matrices for each dataset were
566 obtained from the Gene Expression Omnibus (GEO)⁴⁹ and their metadata from the R package
567 GEOquery⁵⁰. To standardize the gene identifiers as HGNC symbols, we used the R package
568 biomaRT⁵¹. For reprocessing of reads in the GSE206023 study, FASTQ files were
569 downloaded directly from GEO under the accession number GSE206023. **The details of the**
570 **dataset and its accession numbers can be found in Supplementary Table ST1.** The
571 average number of reads per sample was approximately 36 million after trimming, which can
572 also be found in the supplementary material. Quality control of raw and trimmed reads was
573 performed using FastQC v.0.11.8 (Andrews, 2010). Trimming of the adapter content and
574 quality trimming was performed using Trimmomatics v0.36, with the following settings:
575 LEADING 20 TRAILING 20 SLIDINGWINDOW 4:25 MINLEN 31, and the Kallisto index
576 was built with reference transcriptome GRCh38 (Ensembl) with a k-mer length of 31 using
577 the Kallisto v.46.0 programs, and the abundance of the transcripts was quantified using the
578 Kallisto pseudo-alignment, which provides estimates of transcript levels^{17,52,53}. Subsequently,
579 we used the tximport R package to summarize count estimates at the gene level⁵⁴.

580 Differential gene expression analysis

581 Differential gene expression analysis was performed independently for each dataset using the
582 R package DESeq2⁵⁵. We used the Wald test with the interaction terms vaccine and time
583 point. DEGs were filtered based on the Benjamini-Hochberg adjusted p-values ($\text{padj} < 0.05$).
584 We classified up and downregulated genes by \log_2 fold change ($-1 < \text{L2FC} < 1$, respectively).

585 Gene set enrichment analysis

586 The ontology of biological processes within the immune system ["immune system process"
587 (GO:0002376)] was obtained from the GO.db package⁵⁶. To facilitate subsequent analyses,
588 biological processes associated with the immune system were categorized into three distinct
589 groups: "Immune system," "Immune subsystem," and, when related to specific cells, classified
590 under the "Immune cell" category. The VAX MSigDB database was obtained via the MSigDB
591 portal and manually annotated with the available information on the dataset. We used only
592 peripheral blood mononuclear cell-derived samples. The enrichment analysis of DESeq2
593 results was conducted with ImmuneGO using the Enricher and ClusterProfiler packages for
594 over-representation analysis (ORA) and gene set enrichment analysis (GSEA)⁵⁷. Heatmaps
595 were visualized using the ComplexHeatmap package in R and Morpheus
596 (<https://software.broadinstitute.org/morpheus>)^{58,59}.

597 **Principal component analysis and machine learning classification**

598 PCA was performed using L2FC values of immune-related DEGs, through the factoextra R
599 package⁶⁰. For cluster analysis, we used the k-nearest neighbors (KNN) algorithm. To
600 optimize the efficiency of our random forest classification, we initially filtered genes based
601 on their cosine squared values in the first two principal components, setting a threshold above
602 0.5. We then constructed our random forest classifier by leveraging the tidymodels package
603 (Kuhn & Wickam, 2020). Our dataset was partitioned into training (70%) and testing (30%)
604 sets, with stratification for the "type" variable and upsampling to address class imbalance.
605 Employing cross-validation, we fine-tuned the model's hyperparameters using a grid search
606 method within the tidymodels framework. Performance evaluation metrics, including AUC,
607 ROC, OOB, and accuracy, guided the optimization of hyperparameters, including mtry and
608 min_n. Finally, the optimized random forest model was trained on the entire training dataset
609 and subsequently assessed on the testing dataset to evaluate its predictive performance.

610 **Data and code availability**

611 Raw and processed data, as well as codes used are available on the project Github repository
612 (https://github.com/wapsyed/covidvax_atlas).

613 **Author Contributions:**

614 WAPS, DLMF — Conceptualization and manuscript writing;

615 LV, AL, NC, EC, JSD — Manuscript contributions;

616 WAPS, DLMF, SZP — Data analysis;

617 OC, HIN, LFS, ISF, GW, RDC, NOSC, HDD, HDO, ECS, JEK – Review and editing;

618 GCM, OCM, HIN – Supervision, editing, and approval of the final version.

619 **Funding:** We thank the São Paulo Research Foundation (FAPESP grants 2019/14526-0 and
620 2020/05146-7 to GCM; 2018/18886-9 to OCM; 2023/07806-2 to ISF; 2020/16246-2 and
621 2023/13356-0 to DLMF; 2019/01255-9 and 2021/03684-4 to RDC) for financial support. We
622 acknowledge the National Council for Scientific and Technological Development (CNPq)
623 Brazil (grants: 309482/2022-4 to OCM and 102430/2022-5 to LFS).

624 **Conflicts of Interest:** The authors declare that they have no competing interests.

625 Tables

Vaccination								
Vaccine	Commercial name	Regimen	Timepoints (days)	Doses	Technology	Adjuvant	GSE ID	Participants
BNT162b2 (BNT)	Comirnaty	HO	0, 1, 6	3x BNT	RNA	No	GSE199750	25
		HO	0, 1, 6	2x BNT	RNA	No	GSE199750	46
		HO	0, 6	1x BNT	RNA	No	GSE199750	67
		HE	0, 1, 3, 7	1x ChAd + VV + RNA 1x BNT	No	GSE201530	16	
		HE	1	2x ChAd + VV + RNA 1x BNT	No	GSE199750	5	
		BI	10, 26, 51	2x BNT + RNA + I 1x I	No	GSE201530	13	
		BI	10, 26, 51	1x BNT (10RNA + I dpi) + 1x I	No	GSE189039	5	
		AI	10	1x BNT + RNA + I 1x I + 1x BNT	No	GSE189039	2	
		AI	0, 10, 26, 51	1x I + RNA + I + RNA + I + 1x I	No	GSE201530	1	

AZD1222 (ChAd)	Covishield, Vaxzebia	HO	0, 1, 3, 6, 7	2x ChAd	VV	No	GSE199750, 12 GSE201533
		HO	0, 3, 6	1x ChAd	VV	No	GSE199750, 53 GSE201533
		HE	0, 1, 3, 7	1x ChAd + VV + RNA 1x BNT		No	GSE201530 17
		HE	1	2x ChAd + VV + RNA 1x BNT		No	GSE199750 5
mRNA-1273 (MO)	Spikevax	HE	1	2x BNT + RNA 1x MO		No	GSE199750 10
BBIBP-CorV (BBIBP)	Covilo	HO	0, 7, 14, 28	3 (3rd dose) IN		Alum	GSE206023 6
ZF2001	Zifivax	HE	0, 7, 14, 28	1 (3rd dose) SU		Alum	GSE206023 6


626

Infection						
GSE ID	Prior infection	Prior vaccination	Timepoints (days)	Variant	Severity	Participants
GSE189039	No	Yes	0, 10, 26, 51	Beta	MI (1), S (3)	4
	No	No	0, 10, 26, 51	Beta	MO (2), S (3)	5
GSE201530	No	No	0, 1, 3, 5	Omicron	MI	1
	Yes	No	0, 1, 3, 5	Omicron	MI	6
	No	Yes	0, 1, 3, 5	Omicron	MI	38

627

628 **Table 1.** Vaccines and infection conditions selected in this study. Legend: HO: Homologous;
629 HE: Heterologous; BI: Before infection; AI: After infection; I: Infection; RNA: mRNA; VV:
630 Viral vector; IN: Inactivated; SU: Subunit. MI: Mild; MO: Moderate; S: Severe; A:
631 Asymptomatic.


632 **Figures**



633

634 **Fig. 1.** Methods and description of datasets and study population. (A) We manually curated
 635 the GEO datasets and performed differential gene expression analysis. Finally, genes from
 636 immune system biological process (GO:) and the VAX collection from MSigDB were used
 637 in GSEA and ORA, and individual gene expression analysis was analyzed across the studied
 638 conditions. Created with Biorender. Number of participants (B) and samples (C) were
 639 categorized by vaccine and infection conditions. Legend: BBIBP: BBIBP-CORV; BNT:
 640 BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated.


641



642

643 **Fig. 2.** A. Differentially expressed genes (DEGs) were categorized as up- (left panel) and
 644 down-regulated (right panel) with the absolute and relative number of genes. The conditions
 645 were then plotted with the total number of genes and immune genes. Labels correspond to
 646 the total number of immune genes and the percentage over total DEGs. B. Shared DEGs between
 647 infection and vaccination. The upper-left cluster include individuals infected for the first time,
 648 and the bottom-right cluster comprise the first week of vaccination by RNA, VV, and SU
 649 vaccines. C. Twenty most shared immune-related genes. Legend: BBIBP: BBIBP-CORV;
 650 BNT: BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated; IN:
 651 Inactivated; RNA: mRNA vaccines; SU: Subunit; VV: Viral vector. B. Shared DEGs in
 652 vaccination and infection.

Figure 3




653

654 **Fig. 3.** Principal component analysis. A. Two principal components were employed to plot all
 655 conditions, capturing 86.2% of the total variance. K-nearest neighbors (KNN) clustering
 656 identified three distinct clusters. Cluster 1 (C1) includes infected patients and overlaps with

657 Cluster 2 (C2). C2 is predominantly characterized by vaccination in healthy individuals,
658 encompassing convalescent patients and non-convalescent individuals. Cluster 3 (C3)
659 comprises the initial three days post-vaccination with mRNA vaccines and ChAd. B. The
660 loading plot displays cos2 values for the top 20 genes in PC1 and PC2. The top 20 genes
661 contributing to PC1 (C) and PC2 (D), along with the corresponding Log2 Fold Change
662 (L2FC). Genes were displayed with correspondent log2-fold change ranging from -2 (blue) to
663 2 (red). The left annotation on the heatmap depicts the contribution to different immune
664 processes and cells, with colors corresponding to processes and cells related to the
665 complement system (pink), the innate (greens) and adaptive immune systems (purples), and
666 general processes and cells (leukocytes, black). Legend: BBIBP: BBIBP-CORV; BNT:
667 BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated.

Figure 4




668

669 **Fig. 4.** DEGs with $\text{cos}2 > 0.5$ were used to train a random forest model to predict the types of
 670 vaccines and infection, and the ten most important genes were selected (A). The final model
 671 was selected after an iterative process of hyperparameter tuning. The best model was defined

672 with 2000 trees in the forest, where mtry was set to 6 and min_n to 6. The most important
673 genes were used to plot the log₂-fold change (L2FC) (B). C. Gene set enrichment analysis of
674 COVID-19 vaccines and infection. Major immunological gene sets were enriched with GSEA.
675 Normalized enrichment scores (NES) for enriched gene sets, with circle size corresponding
676 to $-\log(qvalue)$. D. Representation of upregulated (red) and downregulated (blue) genes in
677 COVID-19 conditions associated with various immune biological processes. Visualization IN
678 stacked hierarchical layout was generated using Cytoscape⁶¹. Node size is determined by
679 degree centrality, and node colors are determined by type and infection status. Illustration
680 made in **BioRender**. Legend: BBIBP: BBIBP-CORV; BNT: BNT162b2, ChAd: ChAdOx-1;
681 MO: mRNA-1273; I: Infected; V: Vaccinated.

Figure 5



682


683 **Fig. 5.** Gene-level comparison of COVID-19 vaccines and the MSigDB Vax collection.
 684 Overlapping immune-related (A) and other (B) genes between conditions. C. Genes with the
 685 most sharing between COVID-19 vaccination and other vaccines. Visualization in stacked

686 hierarchical layout was generated using Cytoscape⁶¹. C. All immune-related genes shared at
687 least once between conditions. D. Genes included in the first cluster (see complete heatmap
688 in **Fig. S9**) were set with L2FC as 1 (upregulated) and -1 (downregulated). These genes were
689 annotated by their corresponding contribution to subprocesses and cells among the innate,
690 adaptive and complement immune systems (left). E. Over-representation analysis of vaccines
691 against COVID-19 and other pathogens with immune cells and processes. Legend: BBIBP:
692 BBIBP-CORV; BNT: BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V:
693 Vaccinated.



694

695 Supplementary Material

696 Supplementary Figures




All selection step 1 datasets




698 **Fig. S1.** Data curation. Datasets were obtained from NCBI BioProject and curated. All
 699 datasets, including the selected and non-selected, were classified by vaccine technology and
 700 vaccination regimen, and by sample source.

701



702



703 **Fig. S2.** Description of the selected datasets. The datasets include healthy vaccinees without
704 prior infection, infected patients without vaccination, and patients with prior full or
705 incomplete vaccination. Sample collection timelines are shown as black lines, with red lines
706 indicating the first sample collection during hospitalization and gray lines representing events
707 without sample collection. Days post-infection or vaccination are depicted, with blue lines
708 representing hospitalization periods and purple lines indicating dexamethasone treatment.




709

710 **Fig. S3.** DEGs were categorized as up- (A) and down-regulated (B) with the absolute and
 711 relative number of genes, and grouped based on infection (red) and vaccination (blue)

712 conditions. The conditions were then plotted with the relative number of genes corresponding
713 to their roles in essential biological processes, namely immune system, cellular processes,
714 metabolism, and regulation of biological processes, respectively. Shapes correspond to type,
715 colors to disease or infection, and size to total number of DEGs. I: Infection; IN: Inactivated;
716 RNA: mRNA vaccines; SU: Subunit; VV: Viral vector.




718 **Fig. S4.** A. Shared non-immune-related DEGs between infection and vaccination. B. Twenty
719 most shared immune-related genes. BBIBP: BBIBP-CORV; BNT: BNT162b2, ChAd:
720 ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated; IN: Inactivated; RNA: mRNA
721 vaccines; SU: Subunit; VV: Viral vector.




722

723 **Fig. S5.** Genes related to complement system, antimicrobial response, and innate immune
724 system processes and cells. I: Infection; IN: Inactivated; RNA: mRNA vaccines; SU: Subunit;
725 VV: Viral vector.




726

727 **Fig. S6.** Genes related to humoral adaptive immune system, including B cell processes and
728 immunoglobulin-mediated response. I: Infection; IN: Inactivated; RNA: mRNA vaccines;
729 SU: Subunit; VV: Viral vector.



730

731 **Fig. S7.** Genes related to the cellular adaptive immune system, including cellular response
732 and T- and T helper cell processes. I: Infection; IN: Inactivated; RNA: mRNA vaccines; SU:
733 Subunit; VV: Viral vector.



735 **Fig. S8.** General leukocyte processes. I: Infection; IN: Inactivated; RNA: mRNA vaccines;
736 SU: Subunit; VV: Viral vector.



737
738 **Fig. S9.** Gene expression in vaccination against COVID-19 and other pathogens. I: Infection;
739 IN: Inactivated; RNA: mRNA vaccines; SU: Subunit; VV: Viral vector; CONJ: Conjugated;
740 LA: Live-attenuated; VLP: Virus-like particle.

741

742 **References**

- 743 1. Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus
744 outbreak of global health concern. *The Lancet* **395**, 470–473 (2020).
- 745 2. Chung, H. W. *et al.* Effects of government policies on the spread of COVID-19
746 worldwide. *Sci Rep* **11**, 20495 (2021).
- 747 3. Xia, S., Wang, L., Zhu, Y., Lu, L. & Jiang, S. Origin, virological features, immune
748 evasion and intervention of SARS-CoV-2 Omicron sublineages. *Signal*
749 *Transduct Target Ther* **7**, 241 (2022).
- 750 4. Watson, O. J. *et al.* Global impact of the first year of COVID-19 vaccination: a
751 mathematical modelling study. *Lancet Infect Dis* **22**, 1293–1302 (2022).
- 752 5. Li, Y. *et al.* A Comprehensive Review of the Global Efforts on COVID-19
753 Vaccine Development. *ACS Cent Sci* **7**, 512–533 (2021).
- 754 6. World Health Organization (WHO). Status of COVID-19 Vaccines within WHO
755 EUL/PQ evaluation process.
756 [https://extranet.who.int/prequal/sites/default/files/document_files/Status_COVI](https://extranet.who.int/prequal/sites/default/files/document_files/Status_COVID_VAX_08August2023.pdf)
757 [D_VAX_08August2023.pdf](https://extranet.who.int/prequal/sites/default/files/document_files/Status_COVID_VAX_08August2023.pdf) (2023).
- 758 7. Mathieu, E. *et al.* A global database of COVID-19 vaccinations. *Nat Hum Behav*
759 **5**, 947–953 (2021).
- 760 8. Atmar, R. L. *et al.* Homologous and Heterologous Covid-19 Booster
761 Vaccinations. *New England Journal of Medicine* **386**, 1046–1057 (2022).
- 762 9. Vasconcelos, Z. S. *et al.* Immunogenicity Characterization of COVID-19
763 Vaccines: A Systematic Review and Meta-analysis. *Rev Soc Bras Med Trop*
764 **56**, (2023).
- 765 10. Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to
766 new developments. *Nat Rev Immunol* **21**, 83–100 (2021).
- 767 11. Costa Clemens, S. A. *et al.* Heterologous versus homologous COVID-19
768 booster vaccination in previous recipients of two doses of CoronaVac COVID-

- 769 19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind,
770 randomised study. *The Lancet* **399**, 521–529 (2022).
- 771 12. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2
772 Vaccine. *New England Journal of Medicine* **384**, 403–416 (2021).
- 773 13. Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine
774 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised
775 controlled trials in Brazil, South Africa, and the UK. *The Lancet* **397**, 99–111
776 (2021).
- 777 14. Dai, L. *et al.* Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine
778 ZF2001 in Adults. *New England Journal of Medicine* **386**, 2097–2111 (2022).
- 779 15. Al Kaabi, N. *et al.* Effect of 2 Inactivated SARS-CoV-2 Vaccines on
780 Symptomatic COVID-19 Infection in Adults. *JAMA* **326**, 35 (2021).
- 781 16. Wu, N. *et al.* Long-term effectiveness of COVID-19 vaccines against infections,
782 hospitalisations, and mortality in adults: findings from a rapid living systematic
783 evidence synthesis and meta-analysis up to December, 2022. *Lancet Respir*
784 *Med* **11**, 439–452 (2023).
- 785 17. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic
786 RNA-seq quantification. *Nat Biotechnol* **34**, 525–527 (2016).
- 787 18. Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based
788 genome alignment and genotyping with HISAT2 and HISAT-genotype. *Nat*
789 *Biotechnol* **37**, 907–915 (2019).
- 790 19. Romero Starke, K. *et al.* The isolated effect of age on the risk of COVID-19
791 severe outcomes: a systematic review with meta-analysis. *BMJ Glob Health* **6**,
792 e006434 (2021).
- 793 20. Knabl, L. *et al.* BNT162b2 vaccination enhances interferon-JAK-STAT-
794 regulated antiviral programs in COVID-19 patients infected with the SARS-
795 CoV-2 Beta variant. *Communications Medicine* **2**, 17 (2022).

- 796 21. Haseeb, Pirzada, Ain & Choi. Wnt Signaling in the Regulation of Immune Cell
797 and Cancer Therapeutics. *Cells* **8**, 1380 (2019).
- 798 22. Xiao, Y., Peperzak, V., Keller, A. M. & Borst, J. CD27 Instructs CD4+ T Cells
799 to Provide Help for the Memory CD8+ T Cell Response after Protein
800 Immunization. *The Journal of Immunology* **181**, 1071–1082 (2008).
- 801 23. Mohan, T., Zhu, W., Wang, Y. & Wang, B.-Z. Applications of chemokines as
802 adjuvants for vaccine immunotherapy. *Immunobiology* **223**, 477–485 (2024).
- 803 24. Adewoye, A. B. *et al.* Human CCL3L1 copy number variation, gene expression,
804 and the role of the CCL3L1-CCR5 axis in lung function. *Wellcome Open Res*
805 **3**, 13 (2024).
- 806 25. Merad, M., Blish, C. A., Sallusto, F. & Iwasaki, A. The immunology and
807 immunopathology of COVID-19. *Science (1979)* **375**, 1122–1127 (2022).
- 808 26. Afzali, B., Noris, M., Lambrecht, B. N. & Kemper, C. The state of complement
809 in COVID-19. *Nat Rev Immunol* **22**, 77–84 (2022).
- 810 27. Almuqrin, A. *et al.* SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human
811 cell lines reveals low levels of viral backbone gene transcription alongside very
812 high levels of SARS-CoV-2 S glycoprotein gene transcription. *Genome Med*
813 **13**, 43 (2021).
- 814 28. Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics*
815 **27**, 1739–1740 (2011).
- 816 29. DiazGranados, C. A. *et al.* Efficacy of High-Dose versus Standard-Dose
817 Influenza Vaccine in Older Adults. *New England Journal of Medicine* **371**, 635–
818 645 (2014).
- 819 30. Piras-Douce, F. *et al.* Next generation live-attenuated yellow fever vaccine
820 candidate: Safety and immuno-efficacy in small animal models. *Vaccine* **39**,
821 1846–1856 (2021).
- 822 31. Behrens, R. H. & Patel, V. Avoiding shoulder injury from intramuscular
823 vaccines. *The Lancet* **397**, 471 (2021).


- 824 32. Salgado-Albarrán, M. *et al.* Comparative transcriptome analysis reveals key
825 epigenetic targets in SARS-CoV-2 infection. *NPJ Syst Biol Appl* **7**, 21 (2021).
- 826 33. Delorey, T. M. *et al.* COVID-19 tissue atlases reveal SARS-CoV-2 pathology
827 and cellular targets. *Nature* **595**, 107–113 (2021).
- 828 34. Pereira, N. L. *et al.* COVID-19: Understanding Inter-Individual Variability and
829 Implications for Precision Medicine. *Mayo Clin Proc* **96**, 446–463 (2021).
- 830 35. Liang, F. *et al.* Efficient Targeting and Activation of Antigen-Presenting Cells
831 In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.
832 *Molecular Therapy* **25**, 2635–2647 (2017).
- 833 36. Karikó, K. *et al.* Incorporation of Pseudouridine Into mRNA Yields Superior
834 Nonimmunogenic Vector With Increased Translational Capacity and Biological
835 Stability. *Molecular Therapy* **16**, 1833–1840 (2008).
- 836 37. Xia, X. Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and
837 Moderna mRNA Vaccines. *Vaccines (Basel)* **9**, 734 (2021).
- 838 38. Dicks, M. D. J. *et al.* A Novel Chimpanzee Adenovirus Vector with Low Human
839 Seroprevalence: Improved Systems for Vector Derivation and Comparative
840 Immunogenicity. *PLoS One* **7**, e40385 (2012).
- 841 39. Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E. & Blasi, M. The use of viral
842 vectors in vaccine development. *NPJ Vaccines* **7**, 75 (2022).
- 843 40. Nordström, P., Ballin, M. & Nordström, A. Effectiveness of heterologous
844 ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic
845 Covid-19 infection in Sweden: A nationwide cohort study. *The Lancet Regional
846 Health - Europe* **11**, 100249 (2021).
- 847 41. Wang, H. *et al.* Development of an Inactivated Vaccine Candidate, BBIBP-
848 CorV, with Potent Protection against SARS-CoV-2. *Cell* **182**, 713-721.e9
849 (2020).

- 850 42. Zhang, Y. *et al.* Real-world study of the effectiveness of BBIBP-CorV
851 (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. *BMC Public Health*
852 **22**, 1584 (2022).
- 853 43. Sanders, B., Koldijk, M. & Schuitemaker, H. Inactivated Viral Vaccines. in
854 *Vaccine Analysis: Strategies, Principles, and Control* 45–80 (Springer Berlin
855 Heidelberg, 2015). doi:10.1007/978-3-662-45024-6_2.
- 856 44. Aydililo, T. *et al.* Transcriptome signatures preceding the induction of anti-stalk
857 antibodies elicited after universal influenza vaccination. *NPJ Vaccines* **7**, 160
858 (2022).
- 859 45. Chen, Y. *et al.* Immunity Induced by Inactivated SARS-CoV-2 Vaccine:
860 Breadth, Durability, Potency, and Specificity in a Healthcare Worker Cohort.
861 *Pathogens* **12**, 1254 (2023).
- 862 46. Patton, M. J. *et al.* COVID-19 bacteremic co-infection is a major risk factor for
863 mortality, ICU admission, and mechanical ventilation. *Crit Care* **27**, 34 (2023).
- 864 47. Sette, A. & Crotty, S. Immunological memory to <scp>SARS-CoV</scp> -2
865 infection and <scp>COVID</scp> -19 vaccines. *Immunol Rev* **310**, 27–46
866 (2022).
- 867 48. Pulendran, B., S. Arunachalam, P. & O’Hagan, D. T. Emerging concepts in the
868 science of vaccine adjuvants. *Nat Rev Drug Discov* **20**, 454–475 (2024).
- 869 49. Edgar, R. Gene Expression Omnibus: NCBI gene expression and hybridization
870 array data repository. *Nucleic Acids Res* **30**, 207–210 (2024).
- 871 50. Davis, S. & Meltzer, P. S. GEOquery: a bridge between the Gene Expression
872 Omnibus (GEO) and BioConductor. *Bioinformatics* **23**, 1846–1847 (2007).
- 873 51. Durinck, S. *et al.* BioMart and Bioconductor: a powerful link between biological
874 databases and microarray data analysis. *Bioinformatics* **21**, 3439–3440 (2024).
- 875 52. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for
876 Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).


- 877 53. Hunt, S. E. *et al.* Ensembl variation resources. *Database* **2018**, (2018).
- 878 54. Sonesson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq:
879 transcript-level estimates improve gene-level inferences. *F1000Res* **4**, 1521
880 (2016).
- 881 55. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
882 dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 883 56. Carlson, M. GO.db: A set of annotation maps describing the entire Gene
884 Ontology. *R package version 3.8.2*.
- 885 57. Wu, T. *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting
886 omics data. *The Innovation* **2**, 100141 (2021).
- 887 58. Gu, Z. Complex heatmap visualization. *iMeta* **1**, (2022).
- 888 59. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and
889 correlations in multidimensional genomic data. *Bioinformatics* **32**, 2847–2849
890 (2016).
- 891 60. Lê, S., Josse, J. & Husson, F. **FactoMineR**: An R Package for Multivariate
892 Analysis. *J Stat Softw* **25**, (2008).
- 893 61. Shannon, P. *et al.* Cytoscape: A Software Environment for Integrated Models
894 of Biomolecular Interaction Networks. *Genome Res* **13**, 2498–2504 (2003).
- 895

Figure 2


A








B



C









Immune system cells and process

- OTHER
- COMPLEMENT IMS
- INNATE IMS
- INFLAMMATION
- ANTIVIRAL AND IFN
- EOSINOPHIL
- MAST CELL
- NEUTROPHIL
- NK CELL
- ARPP
- DENDRITIC CELLS
- MACROPHAGES
- MONOCYTES
- ADAPTIVE IMS
- CELLULAR ADAPTIVE IMS
- T CELLS
- HUMORAL ADAPTIVE IMS
- IG MEDIATED RESPONSE
- B CELLS



medRxiv preprint doi: <https://doi.org/10.1101/2024.05.22.24307750>; this version posted June 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Figure 5



medRxiv preprint doi: <https://doi.org/10.1101/2024.05.22.24037755>; this version posted June 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Table 1

Vaccination								
Vaccine	Commercial name	Regimen	Timepoints (days)	Doses	Technology	Adjuvant	GSE ID	Participants
BNT162b2 (BNT)	Comirnaty	HO	0, 1, 6	3x BNT	RNA	No	GSE199750	25
		HO	0, 1, 6	2x BNT	RNA	No	GSE199750	46
		HO	0, 6	1x BNT	RNA	No	GSE199750	67
		HE	0, 1, 3, 7	1x ChAd + 1x BNT	VV + RNA	No	GSE201530	16
		HE	1	2x ChAd + 1x BNT	VV + RNA	No	GSE199750	5
		BI	10, 26, 51	2x BNT + 1x I	RNA + I	No	GSE201530	13
		BI	10, 26, 51	1x BNT (10 dpi) + 1x I	RNA + I	No	GSE189039	5
		AI	10	1x BNT + 1x I + 1x BNT	RNA + I	No	GSE189039	2
AZD1222 (ChAd)	Covishield, Vaxzebria	AI	0, 10, 26, 51	1x I + RNA + 1x I	I + RNA + I	No	GSE201530	1
		HO	0, 1, 3, 6, 7	2x ChAd	VV	No	GSE199750, GSE201533	12
		HO	0, 3, 6	1x ChAd	VV	No	GSE199750, GSE201533	53
		HE	0, 1, 3, 7	1x ChAd + 1x BNT	VV + RNA	No	GSE201530	17
		HE	1	2x ChAd + 1x BNT	VV + RNA	No	GSE199750	5
		HE	1	2x BNT + 1x MO	RNA	No	GSE199750	10
mRNA-1273 (MO)	Spikevax	HE	1	2x BNT + 1x MO	RNA	No	GSE199750	10
BBIBP-CorV (BBIBP)	Covilo	HO	0, 7, 14, 28	3 (3rd dose)	IN	Alum	GSE206023	6
ZF2001	Zifivax	HE	0, 7, 14, 28	1 (3rd dose)	SU	Alum	GSE206023	6

Infection						
GSE ID	Prior infection	Prior vaccination	Timepoints (days)	Variant	Severity	Participants
GSE189039	No	Yes	0, 10, 26, 51	Beta	MI (1), S (3)	4
	No	No	0, 10, 26, 51	Beta	MO (2), S (3)	5
GSE201530	No	No	0, 1, 3, 5	Omicron	MI	1
	Yes	No	0, 1, 3, 5	Omicron	MI	6
	No	Yes	0, 1, 3, 5	Omicron	MI	38

Table 1. Vaccines and infection conditions selected in this study. Legend: HO: Homologous; HE: Heterologous; BI: Before infection; AI: After infection; I: Infection; VV: Viral vector; IN: Inactivated; SU: Subunit. MI: Mild; MO: Moderate; S: Severe; A: Asymptomatic.